Therefore, NF-κB inhibition by SFN (20 μmol/L) impairs CSC features in pancreatic cancer cells and enhances their sensitivity to sorafenib chemotherapy [280]. This evidence concerns the gene NFKB1 and familial pancreatic carcinoma.